The TNM and WHO classifications of neuroendoctine neoplasia of the pancreas

Kochatkov A.V.; Zamolodchikov R.D.; Golubev G.K.

doi:https://doi.org/

Kochatkov A.V.

Institut khirurgii im. A.V. Vishnevskogo, Moskva

Zamolodchikov R.D.

Institut khirurgii im. A.V. Vishnevskogo Minzdrava RF, Moskva

Golubev G.K.

Institut problem peredachi informatsii im. A.A. Kharkevicha, Moskva

The TNM and WHO classifications of neuroendoctine neoplasia of the pancreas

Authors:

Kochatkov A.V., Zamolodchikov R.D., Golubev G.K.

More about the authors

Journal: Pirogov Russian Journal of Surgery. 2013;(10): 63‑71

Read: 777 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Kochatkov AV, Zamolodchikov RD, Golubev GK. The TNM and WHO classifications of neuroendoctine neoplasia of the pancreas. Pirogov Russian Journal of Surgery. 2013;(10):63‑71. (In Russ.)

Подписка 2026 Хирургия. Журнал им. Н.И. Пирогова (Pirogov Russian Journal of Surgery)

Использование инфографики авторами научных работ

References:

Bilimoria К.Y., Bentrem D.J., Merkow R.P., Tomlinson J.S., Stewart А.К., Ко С.Y., Talamonti M.S. Application of the pancreatic adenocarcinoma staging system to pancreatic neuroendocrine tumors. J Am Coll Surg 2007; 205: 4: 558-563.
Bosman F.T. WHO classification of tumours of the digestive system. World Health Organization classification of tumours. IARC 2010; 3: 417.
Casadei R., Ricci C., Pezzilli R., Campana D., Tomassetti P., Calculli L., Santini D., Antonacci N., Minni F. Value of both WHO and TNM classification systems for patients with pancreatic endocrine tumors: results of a single-center series. World J Surg 2009; 33: 11: 2458-2463.
DeLellis R.A., Lloyd R.V., Heitz P.U., Eng C. World Health Organization classification of tumours, pathology and genetics of tumours of endocrine organs. Lyon: IARC 2004.
Edge S.В., Compton С. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010; 17: 6: 1471-1474.
Ekeblad S., Skogseid В., Dunder K., Oberg K., Eriksson B. Prognostic factors and survival in 324 patients with pancreatic endocrine tumor treated at a single institution. Clin Cancer Res 2008; 14: 23: 7798-7803.
Fischer L., Kleeff J., Esposito I., Hinz U., Zimmermann A., Friess H., Buchler M.W. Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas. Br J Surg 2008; 95: 5: 627-635.
Goh В.K., Chow P.K., Tan Y.M., Cheow P.С., Chung Y.F., Soo К.C., Wong W.K., Ooi L.L. Validation of five contemporary prognostication systems for primary pancreatic endocrine neoplasms: results from a single institution experience with 61 surgically treated cases. ANZ J Surg 2011; 81: 1-2: 79-85.
Kloppel G., Rindi G., Perren A., Komminoth P., Klimstra D.S. The ENETS and UICC TNM classification of neuroendocrine tumors of the gastrointestinal tract and the pancreas: comment. Pathologe 2010; 31: 5: 353-354.
Kulke M.H., Anthony L.В., Bushnell D.L., de Herder W.W., Goldsmith S.J., Klimstra D.S., Marx S.J., Pasieka J.L., Pommier R.F., Yao J.C., Jensen R.T. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. Pancreas 2010; 39: 6: 735-752.
La Rosa S., Klersy C., Uccella S., Dainese L., Albarello L., Sonzogni A., Doglioni C., Capella C., Solcia E. Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors. Hum Pathol 2009; 40: 1: 30-40.
Oh T.G., Chung M.J., Park J.Y., Bang S.M., Park S.W., Chung J.В., Song S.Y. Prognostic factors and characteristics of pancreatic neuroendocrine tumors: single center experience. Yonsei Med J 2012; 53: 5: 944-951.
Panzuto F., Boninsegna L., Fazio N., Campana D., Pia Brizzi M., Capurso G., Scarpa A., De Braud F., Dogliotti L., Tomassetti P., Delle Fave G., Falconi M. Metastatic and locally advanced pancreatic endocrine carcinomas: analyis of factors associated with disease progression. J Clin Oncol 2011; 29: 17: 2372-2377.
Pape U.F., Jann H., Muller-Nordhorn J., Bockelbrink A., Berndt U., Willich S.N., Koch M., Rocken C., Rindi G., Wiedenmann B. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer 2008; 113: 2: 256-265.
Pomianowska E., Gladhaug I.P., Grzyb K., Rosok В.I., Edwin В., Bergestuen D.S., Mathisen O. Survival following resection of pancreatic endocrine tumors: importance of R-status and the WHO and TNM classification systems. Scand J Gastroenterol 2010; 45: 7-8: 971-979.
Rindi G., Falconi M., Klersy C., Albarello L., Boninsegna L., Buchler M.W., Capella C., Caplin M., Couvelard A., Doglioni C., Delle Fave G., Fischer L., Fusai G., de Herder W.W., Jann H., Komminoth P., de Krijger R.R., La Rosa S., Luong Т.V., Pape U., Perren A., Ruszniewski P., Scarpa A., Schmitt A., Solcia E., Wiedenmann B. TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study. J Natl Cancer Inst 2012; 104: 10: 764-777.
Rindi G., Kloppel G., Alhman H., Caplin M., Couvelard A., de Herder W.W., Erikssson В., Falchetti A., Falconi M., Komminoth P., Korner M., Lopes J.M., McNicol A.M., Nilsson O., Perren A., Scarpa A., Scoazec J.Y., Wiedenmann В. Frascati Consensus Conference p., European Neuroendocrine Tumor S. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 2006; 449: 4: 395-401.
Scarpa A., Mantovani W., Capelli P., Beghelli S., Boninsegna L., Bettini R., Panzuto F., Pederzoli P., delle Fave G., Falconi M. Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patients. Mod Pathol 2010; 23: 6: 824-833.
Sellner F., Thalhammer S., Stattner S., Karner J., Klimpfmger M. TNM stage and grade in predicting the prognosis of operated, non-functioning neuroendocrine carcinoma of the pancreas - a single-institution experience. J Surg Oncol 2011; 104: 1: 17-21.
Strosberg J.R., Cheema A., Weber J., Han G., Coppola D., Kvols L.K. Prognostic validity of a novel American Joint Committee on Cancer Staging Classification for pancreatic neuroendocrine tumors. J Clin Oncol 2011; 29: 22: 3044-3049.
Strosberg J.R., Cheema A., Weber J.M., Ghayouri M., Han G., Hodul P.J., Kvols L.K. Relapse-free survival in patients with nonmetastatic, surgically resected pancreatic neuroendocrine tumors: an analysis of the AJCC and ENETS staging classifications. Ann Surg 2012; 256: 2: 321-325.
Tsuchiya A., Koizumi M., Ohtani H. World Health Organization Classification (2004)-based re-evaluation of 95 nonfunctioning "malignant" pancreatic endocrine tumors reported in Japan. Surg Today 2009; 39: 6: 500-509.
Wang D.S., Zhang D.S., Qiu M.Z., Wang Z.Q., Luo H.Y., Wang F.H., Li Y., Xu R.H. Prognostic factors and survival in patients with neuroendocrine tumors of the pancreas. Tumour Biol 2011; 32: 4: 697-705.
Yao J.С., Hassan M., Phan A., Dagohoy C., Leary C., Mares J.E., Abdalla E.K., Fleming J.В., Vauthey J.N., Rashid A., Evans D.B. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35 825 cases in the United States. J Clin Oncol 2008; 26: 18: 3063-3072.